Table 2

Baseline characteristics of study population in the included trials

WOSCOPSHPSLIPIDASCOTCORONAJUPITER
Age (years)55.263.962.063.173.066.0
Men (%)100.075.383.081.276.061.8
Caucasian (%)NANANA94.7NA71.2
Diabetes at baseline (%)1.229.011.924.629.50
BMI (kg/m2)26.027.6NA28.727.028.4
Prior MI (%)041.064.0060.00
LDL cholesterol (mg/dl)192.0131.5152.5132.6138.5108.0
HDL cholesterol (mg/dl)44.041.036.350.748.449.0
Triglycerides (mg/dl)163.0186.0136.2146.9178.0118.0
FBG (mg/dl)85.0NA101.0111.7NA94.0
A1C (%)NANANANANA5.7
FBG measurement laboratoryCentralCentralCentralCentralCentralCentral
Concomitant medications (%)
β-BlockersNANA47NA75NA
ThiazidesNANANANA13NA
ACEI/ARBNANA16NA91.5NA
  • Data are means for continuous variables, except for JUPITER, where median values were reported. ACEI, ACE inhibitor; ARB, angiotensin receptor blocker; FBG, fasting blood glucose; MI, myocardial infarction; NA, not available.